6533b854fe1ef96bd12aeb38

RESEARCH PRODUCT

Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases

Antonino TerranovaGiuseppe MontaltoLydia GiannitrapaniEmanuele La SpadaElisa CampagnaF. CartabellottaMonica La SpadaMaurizio Soresi

subject

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLong term follow upSpecialties of internal medicineNormal serumChronic hepatitis CGastroenterologyAntiviral AgentsBody Mass IndexLiver diseaseInterferon treatmentInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesUltrasonography Doppler ColorChronic hepatitis C. Persistently normal transaminases. Liver histology. Progression of disease. Interferon treatment.Proportional Hazards ModelsHepatologymedicine.diagnostic_testbusiness.industrySignificant differenceHistologyAlanine TransaminaseGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryHepatitis C Virus PositiveLiverRC581-951Liver biopsyDisease ProgressionElasticity Imaging TechniquesRNA ViralFemaleBiopsy Large-Core NeedlePersistently normal transaminasesbusinessLiver histologyProgression of disease

description

Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respectively). Twenty patients had flares of ALT and three of them developed LC in a mean time of 162-178 months. Twelve of these patients underwent current antiviral treatment; six patients were SVR. At baseline, the 5 patients who progressed to LC had age and BMI significantly higher than patients without LC (P < 0.005 and P < 0.01, respectively). Grading (P < 0.006) and staging (P < 0.003) were also more severe at histology, while serum HDL-C levels were statistically lower (P < 0.002). Comparing patients with flares of transaminases with and without LC, we found a significant difference at baseline for age, BMI, HDL-C, grading and staging (P < 0.05; P < 0.01 and P < 0.003, respectively). Conclusion. In HCV-RNA positive patients associated with PNALT the grade of disease activity increased over the years in only half of patients and a higher degree of liver fibrosis at baseline was the major relevant factor for progression.

http://www.scopus.com/inward/record.url?eid=2-s2.0-84878760559&partnerID=MN8TOARS